Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Primary Pulmonary Hypertension Differential Diagnoses

  • Author: Ronald J Oudiz, MD, FACP, FACC, FCCP; Chief Editor: Ryland P Byrd, Jr, MD  more...
 
Updated: Jan 27, 2016
 
 

Diagnostic Considerations

Pulmonary vascular disease can be associated with portal hypertension and connective-tissue diseases. Other associations with pulmonary arterial hypertension (PAH) include exposure to anorexigens and likely other alpha-adrenergic stimulants (eg, cocaine, amphetamines) and HIV seropositivity. Other problems to be considered include cor pulmonale, pulmonary embolism, and cardiogenic pulmonary edema.

Go to Cor Pulmonale for more complete information on this topic.

Differential Diagnoses

 
 
Contributor Information and Disclosures
Author

Ronald J Oudiz, MD, FACP, FACC, FCCP Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American Thoracic Society, American College of Physicians, American Heart Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Actelion, Bayer, Gilead, Lung Biotechnology, United Therapeutics<br/>Received research grant from: Actelion, Bayer, Gilead, Ikaria, Lung Biotechnology, Pfizer, Reata, United Therapeutics<br/>Received income in an amount equal to or greater than $250 from: Actelion, Bayer, Gilead, Lung Biotechnology, Medtronic, Reata, United Therapeutics.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University

Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

Acknowledgements

Oleh Wasyl Hnatiuk, MD Program Director, National Capital Consortium, Pulmonary and Critical Care, Walter Reed Army Medical Center; Associate Professor, Department of Medicine, Uniformed Services University of Health Sciences

Oleh Wasyl Hnatiuk, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

References
  1. [Guideline] Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul. 126(1 Suppl):35S-62S. [Medline].

  2. [Guideline] Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 Jun. 131(6):1917-28. [Medline].

  3. [Guideline] McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28. 119(16):2250-94. [Medline]. [Full Text].

  4. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24. 62(25 Suppl):D34-41. [Medline].

  5. DRESDALE DT, SCHULTZ M, MICHTOM RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med. 1951 Dec. 11(6):686-705. [Medline].

  6. Stiles S. Novel PA-Hypertension Gene Variants Identified, Treatment Approach Hinted. Jul 26 2013. Available at http://www.medscape.com/viewarticle/808479. Accessed: Aug 1 2013.

  7. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25. 369(4):351-61. [Medline].

  8. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24. 62(25 Suppl):D34-41. [Medline].

  9. Soon E, Treacy CM, Toshner MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 2011 Apr. 66(4):326-32. [Medline].

  10. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29. 335(9):609-16. [Medline].

  11. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1. 173(9):1023-30. [Medline].

  12. Yigla M, Kramer MR, Bendayan D, Reisner SA, Solomonov A. Unexplained severe pulmonary hypertension in the elderly: report on 14 patients. Isr Med Assoc J. 2004 Feb. 6(2):78-81. [Medline].

  13. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004 Feb 15. 169(4):441-7. [Medline].

  14. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13. 122(2):164-72. [Medline].

  15. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and Outcomes of Patients Diagnosed With Pulmonary Hypertension With Pulmonary Capillary Wedge Pressures of 16-18 mmHg: Insights From REVEAL. Chest. 2012 May 31. [Medline].

  16. [Guideline] McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul. 126(1 Suppl):14S-34S. [Medline]. [Full Text].

  17. [Guideline] Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul. 126(1 Suppl):4S-6S. [Medline].

  18. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006 May. 129(5):1313-21. [Medline].

  19. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation. 2008 Nov 18. 118(21):2183-9. [Medline]. [Full Text].

  20. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003 Aug 19. 108(7):844-8. [Medline].

  21. Chakinala M, McGoon M. Pulmonary Hypertension Care Centers. Adv in PH J. Winter 2014. 12(4):175-8. [Full Text].

  22. [Guideline] Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16. 41(8):1380-6. [Medline].

  23. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr. 157(4):625-35. [Medline].

  24. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997 Aug. 30(2):343-9. [Medline].

  25. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug. 126(2):420-7. [Medline].

  26. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15. 165(6):800-4. [Medline].

  27. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1. 347(5):322-9. [Medline].

  28. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24. 373 (26):2522-33. [Medline].

  29. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21. 346(12):896-903. [Medline].

  30. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10. 117(23):3010-9. [Medline].

  31. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17. 54(21):1971-81. [Medline].

  32. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21. 149(8):521-30. [Medline].

  33. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9. 119(22):2894-903. [Medline].

  34. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25. 369(4):319-29. [Medline].

  35. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25. 369(4):330-40. [Medline].

  36. Wood S. FDA Approves Riociguat for PAH and CTEPH. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/812292. Accessed: October 13, 2013.

  37. FDA. FDA approves Adempas to treat pulmonary hypertension [press release]. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370866.htm. Accessed: October 13, 2013.

  38. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29. 369(9):809-18. [Medline].

  39. Stiles S. SERAPHIN: Macitentan, Novel Endothelin-Receptor Antagonist, Boosts PAH Outcomes. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/810215. Accessed: September 1, 2013.

  40. Wood S. FDA approves macitentan for PAH. Medscape Medical News. October 18, 2013. [Full Text].

  41. FDA. FDA approves Opsumit to treat pulmonary arterial hypertension [press release]. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm371362.htm. Accessed: October 29, 2013.

  42. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27. 373 (9):834-44. [Medline].

  43. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline and Expert Panel Report. Chest. 2014 Aug 1. 146(2):449-75. [Medline]. [Full Text].

  44. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct. 30(20):2493-537. [Medline].

  45. Roubinian N, Elliott CG, Barnett CF, Blanc PD, Chen J, De Marco T, et al. Effects of Commercial Air Travel on Patients with Pulmonary Hypertension. Chest. 2012 Apr 5. [Medline].

  46. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2009 Sep. 34(3):669-75. [Medline].

  47. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15. 121(6):409-15. [Medline].

  48. Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ. 2012 Feb 21. 344:e554. [Medline]. [Full Text].

  49. Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012 Aug 21. 60(8):768-74. [Medline].

  50. FDA Approves Orenitram™ (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension. PR Newswire. Available at http://www.prnewswire.com/news-releases/fda-approves-orenitram-treprostinil-extended-release-tablets-for-the-treatment-of-pulmonary-arterial-hypertension-236816291.html. Accessed: January 6, 2014.

  51. FDA approves Orenitram for treatment of PAH. Healio Cardiology. Available at http://www.healio.com/cardiology/vascular-medicine/news/online/%7B5d67f636-329c-4ecc-b9fe-33c9528ee020%7D/fda-approves-orenitram-for-treatment-of-pah. Accessed: January 9, 2013.

Previous
Next
 
Two-dimensional short-axis echocardiogram image. Note the flattened interventricular septum due to right ventricular overload.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.